T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1
Authors:
Open Access
- 22 June 2012
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 2 (6) , e75
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Overexpression of BMI‐1 correlates with drug resistance in B‐cell lymphoma cells through the stabilization of survivin expressionCancer Science, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- A Systematic Review of Occupational Exposure to Particulate Matter and Cardiovascular DiseaseInternational Journal of Environmental Research and Public Health, 2010
- Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2008
- The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangementHaematologica, 2007
- The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemiaBlood, 2007
- Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphomaLeukemia, 2007
- Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapyBlood, 2007
- Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionOncogene, 2005